Pfizer misses revenue estimates as Covid product sales decline

PFIZER reported a bigger-than-expected 54 per cent decline in second-quarter revenue on Tuesday (Aug 1), as the US drugmaker faced declining demand for its Covid-19 products.

The company has said it expects 2023 to be a low point for Covid product sales following strong demand at the peak of the pandemic before a potential return to growth in 2024.

Pfizer is also preparing for declining revenues in coming years as some of its top-selling drugs are soon set to face competition from cheaper generic treatments.

The company has responded through billion-dollar acquisitions, headlined by the US$43 billion deal for cancer-therapy specialist Seagen, as well stepped up spending on research and development.

Pfizer also trimmed the upper end of its annual revenue forecast, and now expects sales between US$67 billion and US$70 billion, compared with US$67 billion to US$71 billion forecast earlier.

Quarterly sales of vaccine Comirnaty declined 83 per cent to US$1.49 billion, while antiviral treatment Paxlovid sales tumbled 98 per cent to US$143 million.

SEE ALSO

Tornado at Pfizer plant exposes fragility of drug supply chain

THE BUSINESS TIMES INSIGHTS

Powering Asean's Future 2026

Find out how enterprises are navigating power constraints and sustainability targets

ACCESS THE INSIGHTS

Analysts had expected sales of US$1.40 billion for the vaccine and US$1.08 billion for Paxlovid.

Total revenue for the second quarter at US$12.73 billion missed analysts’ estimates of US$13.27 billion, according to Refinitiv data.

Excluding items, Pfizer reported a profit of 67 US cents per share, compared with analysts’ estimates of 57 US cents. REUTERS